Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy
Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administration said it was investigating cancer risks potentially associated with all currently approved products in the class.
CAR-T therapies alter immune cells called T cells so that they can attack cancer cells.
The…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here